Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 24, 2007
- Eli Lilly Japan to Train Staff for Multinational Clinical Trials
December 17, 2007
- Platelet Formation Promoted by Substance Derived from Peanut Skins
December 17, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 17, 2007
- Eisai Ties Up with BioArctic Neuroscience for BAN2401 for Alzheimer's Disease
December 17, 2007
- NBI to Be Fastest-Growing among Top-20 Companies 3 Years in a Row
December 17, 2007
- TSD Japan Licensed COLAL-PRED from Alizyme
December 17, 2007
- Livalo to Rise to 3rd on Statin Market
December 17, 2007
- R&D NEWS IN BRIEF
December 17, 2007
- Combined Sales of 24 Listed Companies Up 5%, Operating Profits Up 24.5%
December 17, 2007
- Subcommittee Approves Proposals for Promotion of the Use of Generics
December 17, 2007
- CMIC Stepping Up from PVC to HVC
December 17, 2007
- 33% of Pharmacists Are in Favor of New Prescription Form: Survey
December 17, 2007
- EPS Aims at \30 Bil. in Sales in 2010
December 17, 2007
- Kurabo Starts Contract HPV Genotyping Services
December 17, 2007
- JapanBridge to Select Anticancer Drug as Its First Product
December 17, 2007
- METIS Inaugurates 3rd-Phase Plan
December 17, 2007
- New Stock Exchange Market NEO to Stimulate Drug Discovery by Bioventures
December 17, 2007
- Medical Devices to Be Re-priced if They Are 1.7 Times More Expensive than Overseas
December 17, 2007
- BUSINESS NEWS IN BRIEF
December 17, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…